CN107343868A - 一种具有祛湿疹功能的组合物及其制备方法 - Google Patents
一种具有祛湿疹功能的组合物及其制备方法 Download PDFInfo
- Publication number
- CN107343868A CN107343868A CN201610293476.8A CN201610293476A CN107343868A CN 107343868 A CN107343868 A CN 107343868A CN 201610293476 A CN201610293476 A CN 201610293476A CN 107343868 A CN107343868 A CN 107343868A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- preparation
- calyx
- persimmon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 206010037844 rash Diseases 0.000 title claims abstract description 11
- 208000010201 Exanthema Diseases 0.000 title claims abstract description 9
- 201000005884 exanthem Diseases 0.000 title claims abstract description 9
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 58
- 241000255789 Bombyx mori Species 0.000 claims abstract description 58
- 241001164374 Calyx Species 0.000 claims abstract description 58
- 240000005250 Chrysanthemum indicum Species 0.000 claims abstract description 58
- 235000018959 Chrysanthemum indicum Nutrition 0.000 claims abstract description 58
- 235000011511 Diospyros Nutrition 0.000 claims abstract description 58
- 244000236655 Diospyros kaki Species 0.000 claims abstract description 58
- 239000003814 drug Substances 0.000 claims abstract description 20
- 239000002537 cosmetic Substances 0.000 claims abstract description 3
- 239000000706 filtrate Substances 0.000 claims description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- 239000000284 extract Substances 0.000 claims description 31
- 230000006837 decompression Effects 0.000 claims description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 22
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 21
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 17
- 239000003921 oil Substances 0.000 claims description 17
- 230000002829 reductive effect Effects 0.000 claims description 17
- 239000008346 aqueous phase Substances 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 16
- 239000002674 ointment Substances 0.000 claims description 16
- 239000012071 phase Substances 0.000 claims description 16
- 238000005119 centrifugation Methods 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 14
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 14
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 11
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 11
- 235000021355 Stearic acid Nutrition 0.000 claims description 11
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 11
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 11
- 239000004302 potassium sorbate Substances 0.000 claims description 11
- 229940069338 potassium sorbate Drugs 0.000 claims description 11
- 235000010241 potassium sorbate Nutrition 0.000 claims description 11
- 239000000377 silicon dioxide Substances 0.000 claims description 11
- 239000008117 stearic acid Substances 0.000 claims description 11
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 10
- 235000011152 sodium sulphate Nutrition 0.000 claims description 10
- 229960000541 cetyl alcohol Drugs 0.000 claims description 9
- 125000005908 glyceryl ester group Chemical group 0.000 claims description 9
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 9
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- 230000002335 preservative effect Effects 0.000 claims description 9
- 241000931705 Cicada Species 0.000 claims description 8
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- 229920005573 silicon-containing polymer Polymers 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003995 emulsifying agent Substances 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000003974 emollient agent Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 229940095672 calcium sulfate Drugs 0.000 claims description 5
- 239000000287 crude extract Substances 0.000 claims description 5
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 235000011132 calcium sulphate Nutrition 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 229940056318 ceteth-20 Drugs 0.000 claims description 4
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 4
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 4
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 3
- 235000010199 sorbic acid Nutrition 0.000 claims description 3
- 239000004334 sorbic acid Substances 0.000 claims description 3
- 229940075582 sorbic acid Drugs 0.000 claims description 3
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 2
- 238000007670 refining Methods 0.000 claims description 2
- 238000001256 steam distillation Methods 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 abstract description 13
- 208000010668 atopic eczema Diseases 0.000 abstract description 13
- 235000019198 oils Nutrition 0.000 description 15
- 230000000694 effects Effects 0.000 description 9
- 208000003251 Pruritus Diseases 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 230000036461 convulsion Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010044684 Trismus Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 201000005404 rubella Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- -1 Stevioside glycosides Chemical class 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 229930015582 oxymatrine Natural products 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- YCSMVPSDJIOXGN-UHFFFAOYSA-N CCCCCCCCCCCC[Na] Chemical compound CCCCCCCCCCCC[Na] YCSMVPSDJIOXGN-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010014198 Eczema infantile Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 240000001519 Verbena officinalis Species 0.000 description 1
- 235000018718 Verbena officinalis Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/44—Ebenaceae (Ebony family), e.g. persimmon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Insects & Arthropods (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有祛湿疹功能的组合物及其制备方法,该组合物主要是由金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕按一定重量配比制备而成,属于化妆品或药品的技术领域,用于湿疹的治疗和防治。
Description
技术领域
本发明涉及一种具有祛湿疹功能的组合物及其制备方法,属于化妆品或药品的技术领域。
背景技术
湿疹是临床常见的一种过敏性皮肤病,病名繁多,称浸淫疮、血风疮、湿毒、风湿疮等,中医上统称为“湿毒疮”。湿疹的发病与风、湿、热三邪有密切关系。其特点为自觉剧烈瘙痒,皮损多形性,对称分布,有渗出倾向,慢性病程,易反复发作。多发生于5岁以内的儿童,也可见于成人。感染单纯疱疹病毒后,约经5-9天潜伏期,突然高热、全身不适、恶心、呕吐及嗜睡等症状。
在湿疹的发病人群中,尤以小儿湿疹最为棘手。婴幼儿的皮肤细嫩,容易受到损伤,故治疗婴幼儿湿疹应该尽量不用或者少用对皮肤健康有影响的化学品,因此,开发一种疗效好且温和不刺激、低敏安全的适合小儿使用的祛湿疹产品尤为必要。
发明内容
本发明主要解决的技术问题是提供一种具有祛湿疹功能的组合物;本发明还提供了该组合物的制备方法。
本发明是通过以下技术方案实现的:
本发明是由下述重量份的原料药制成的:
金银花10-100份、苦参10-100份、蛇床子10-100份、当归10-100份、防风10-100份、柿蒂10-100份、野菊花5-80份、僵蚕5-80份。
优选为:金银花15-60份、苦参15-60份、蛇床子15-60份、当归15-60份、防风15-60份、柿蒂15-60份、野菊花10-50份、僵蚕10-50份。
更优选为:金银花22-50份、苦参22-50份、蛇床子22-50份、当归22-50份、防风22-50份、柿蒂22-50份、野菊花14-30份、僵蚕14-30份。
最佳优选为:金银花22份、苦参22份、蛇床子22份、当归22份、防风22份、柿蒂22份、野菊花14份、僵蚕14份;
或者:金银花50份、苦参50份、蛇床子50份、当归50份、防风50份、柿蒂50份、野菊花30份、僵蚕30份。
本发明中各原料药的作用机理如下:
金银花、野菊花二者功效皆为清热解毒,现代医学研究表明,二者皆有抗菌、抗病毒、抗炎以及促进白细胞吞噬等功能。苦参的主要功效是清热燥湿,袪风杀虫,主湿热泻痢、阴痒、疥癣、麻风、皮肤瘙痒,湿毒疮痈等,常用以治疗皮肤风痒及脓疱疮。现代药理研究证明,苦参对金黄色葡萄球菌、绿脓杆菌及多种皮肤致病性真菌有不同程度的抑制作用,苦参中的氧化苦参碱有抑制IgE 和抗原引起的肥大细胞释放组织胺,使膜流动性降低,但不改变P81 细胞测CAMP 水平,说明氧化苦参碱有抗过敏作用,是苦参抗过敏作用的有效成分。由此证明苦参煎剂外洗治疗急性湿疹有良好的疗效。蛇床子水煎液能降低小鼠腹腔毛细血管通透性,抑制红细胞的溶血现象,稳定细胞膜, 有显著的抗炎作用及免疫抑制作用。当归补血活血、调经止痛、润燥滑肠,主血虚诸证、月经不调、经闭、痛经、症瘕结聚、崩漏、虚寒腹痛、痿痹、肌肤麻木、肠燥便难、赤痢后重、痈疽疮疡、跌扑损伤等,现代研究表明,当归具有抗炎作用,对多种致炎剂引起的急性毛细血管通透性增高、组织水肿及慢性损伤均有显著抑制作用,且能抑制炎症后期肉芽组织增生。防风祛风解表、胜湿止痛、止痉,用于外感表证、风疹瘙痒、风湿痹痛、破伤风正、脾虚湿盛等。柿蒂有降逆下气、清热润肺、生津止渴、健脾化痰的功效。僵蚕具有息风止痉、祛风止痛、化痰散结之功效,常用于肝风夹痰、惊痫抽搐、小儿急惊、破伤风、中风口㖞、风热头痛、目赤咽痛、风疹瘙痒、发颐痄腮。
本发明以苦参、蛇床子清热燥湿,以防风、僵蚕祛风止痒,以当归凉血润燥,以柿蒂保肝解毒,以金银花、野菊花清热解毒,用于湿疹的治疗和防治。
其中,本发明中的柿蒂还可以用蝉蜕替代,蝉蜕疏散风热、利咽开音、透疹、明目退翳、息风止痉,用于风热感冒、温病初起、咽痛音哑、麻疹不透、风疹瘙痒、目赤翳障、急慢惊风、破伤风证、小儿夜啼不安等。《本草纲目》:“蝉,主疗皆一切风热证,古人用身,后人用蜕,大抵治脏府经络,当用蝉身;治皮肤疮疡风热,当用蝉蜕。”
在使用上述药物时,既可以采用以相当于所述重量配比的药物为原料分别净选,干燥、粉碎、混合得到符合制剂要求粒度的颗粒或粉末直接服用。也可以采用以相当于所述重量配比关系的药物为原料经过适当处理后添加药用辅料,根据需要将其制成各种制剂。由上述原料药制备成制剂的过程中,上述原料药可以采用如下方法进行处理:分别加水或不同浓度的乙醇提取,提取液浓缩干燥得粗提物;或进一步采用醇沉法、水返溶法、有机溶剂萃取法、絮凝沉淀法、柱层析法的一种或几种联合使用进行适当精制后得精提物;在对上述有效药用成分进行提取时可采用的具体操作和/或使用方法,既可以是以所述的各比例量的药物成分为原料,分别提取其有效药用成分后再混合的方式,也可以采用按所说比例量的各药物原料混合后再共同提取的方式。采用不同的提取手段、设备及提取时所需的理想或最佳的提取温度、溶剂用量、提取时间、提取次数等具体条件,则可根据实际情况通过试验被筛选和找到。
本发明组合物的制备方法如下:
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕直接粉碎得到粉末;或加水或不同浓度的乙醇提取,提取液浓缩干燥得粗提物;或进一步采用水提醇沉法、有机溶剂萃取法、柱层析法、二氧化碳超临界萃取法、水蒸气蒸馏法进行精制得到精提物;上述粉末或粗提物或精提物即为本发明组合物的有效成分。
制得的有效成分可以直接入药服用或加入药剂学上可接受的辅料按常规工艺制备成所需制剂。如可以制成常用的片剂(分散片、泡腾片、口腔崩解片、含片、咀嚼片、泡腾片)、胶囊剂(硬胶囊、软胶囊)、颗粒剂、丸剂(滴丸剂)、散剂等固体制剂形式的口服药物,也可以制成糖浆、酒剂、酊剂、口服液等液体制剂形式的口服药物;还可以制成膏剂、凝胶剂、软膏剂、乳膏剂、巴布剂、贴膏剂、搽剂、洗剂、涂膜剂等外用制剂形式的外用药物。因此,该药物组合物中除有效成分外,还可以含有药学上可以接受的辅料。
这里所述的辅料,可以根据不同的制剂有所不同,如在片剂、胶囊剂、颗粒剂等固体制剂中常用的稀释剂、崩解剂、赋形剂、粘合剂、润滑剂、表面活性剂、填充剂等;在糖浆、口服液等液体制剂形式中常用的表面活性剂、稀释剂、防腐剂、稳定剂、矫味剂、助流剂等;在凝胶剂、软膏剂等外用制剂形式中常用的药用油性基质、水性基质、防腐剂、抗氧剂、保湿剂、透皮吸收促进剂、润肤剂、增稠剂、增溶剂、pH调节剂、乳化剂、稳定剂、芳香剂等。
其常用辅料如淀粉、乳糖、蔗糖、糊精、糖粉、微晶纤维素、甘露醇、木糖醇、聚乙二醇、硫酸钙、磷酸氢钙、碳酸钙、改良淀粉、山梨醇、聚乙烯吡咯烷酮、重质碳酸镁、羧甲基纤维素钠、羟丙甲基纤维素、甲基纤维素、乙基纤维素、羧甲淀粉钠、羟丙基纤维素、聚维酮K30、白陶土、预胶化淀粉、硬脂酸镁、滑石粉、微粉硅胶、二氧化硅、甜叶菊苷、甜菜碱、阿司帕坦、甘草甜素、糖精钠、冰糖、蜂蜜、蜂蜡、大豆油、麻油、玉米油、花生油、蓖麻油、鱼油、枸橼酸、碳酸氢钠、碳酸钠、卡拉胶、琼脂、明胶、海藻酸钠、甲壳素、黄原胶、瓜耳豆胶、西黄耆胶、阿拉伯胶、槐豆胶、刺梧桐胶、硬脂酸、单硬脂酸甘油酯、聚丙烯酰胺、交联型聚丙烯酸钠、聚乙烯醇、卡波姆、山梨酸、山梨酸钾、羟苯甲酯、羟苯乙酯、羟苯丙酯、苯氧乙醇、苯酚、苯甲醇、尼泊金、硫柳汞、二甲基亚砜、氮酮、三乙醇胺、三乙胺、二乙胺、月桂胺、氢氧化钠、碳酸氢钠、碳酸钠、水溶性霍霍巴油、尿素囊、甘油、丙二醇、丁二醇、异丙醇、乙醇、透明质酸、沙地马鞭草、蚕丝氨酸、聚甲基丙烯酸甘油酯、十二烷基硫酸钠、吐温类、司盘类、聚氧乙烯蓖麻油、聚氧乙烯脂肪醇醚、聚氧乙烯氢化蓖麻油、PEG-40
氢化蓖麻油、PEG-60氢化蓖麻油、鲸蜡醇、甘油硬脂酸酯、PEG-75
硬脂酸酯、鲸蜡硬脂醇、鲸蜡醇聚醚-20、硬脂醇、辛酸/癸酸三甘油酯、硬脂酸、聚二甲基硅氧烷、环五聚二甲基硅氧烷、维生素E、维生素C、谷胱甘肽、薰衣草精油、玫瑰花精油等。
本发明组合物优先被制成散剂或软膏剂。
散剂的制备方法为:
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加6-12倍量水提取1-3次,每次1-3小时,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量辅料,混合均匀,即得散剂。
其中,辅料是指碳酸氢钠、硫酸钠、硅石、甘草酸二钾、磷酸三钙、硫代硫酸钠、硫酸钙、氯化钙、硫酸镁、碳酸钾;优选碳酸氢钠、硫酸钠、硅石、甘草酸二钾。
软膏剂的制备方法为:
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加6-12倍量水提取1-3次,每次1-3小时,过滤,合并滤液,滤液减压浓缩至稠膏,干燥,粉碎,得提取物;
取保湿剂、防腐剂适量,加入提取物和适量纯化水溶解,加热,充分搅拌至完全溶解,即为水相;取乳化剂、稳定剂、润肤剂适量,加热至完全溶化,即为油相;搅拌下将水相缓慢加入油相中,停止加热,继续搅拌,冷却至室温,即得软膏剂。
其中,保湿剂是指指甘油、丙二醇、丁二醇、异丙醇、透明质酸中的一种或一种以上,优选甘油;
防腐剂是指山梨酸钾、山梨酸、羟苯甲酯、羟苯乙酯、羟苯丙酯、苯氧乙醇中的一种或一种以上,优选山梨酸钾;
乳化剂是指鲸蜡醇、甘油硬脂酸酯、PEG-75 硬脂酸酯、鲸蜡硬脂醇、鲸蜡醇聚醚-20中的一种或一种以上,优选鲸蜡醇、甘油硬脂酸酯;
稳定剂是指硬脂醇、卡波姆中的一种或一种以上,优选硬脂醇;
润肤剂是指辛酸/癸酸三甘油酯、硬脂酸、聚二甲基硅氧烷、环五聚二甲基硅氧烷中的一种或一种以上,优选辛酸/癸酸三甘油酯、硬脂酸。
凝胶剂的制备方法为:
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加6-12倍量水提取1-3次,每次1-3小时,过滤,合并滤液,滤液减压浓缩至稠膏,干燥,粉碎,得提取物;
取增稠剂、保湿剂、透皮剂、防腐剂,加入水、pH调节剂,制成凝胶基质,和提取物混合,搅拌均匀,即得凝胶剂。
颗粒剂的制备方法为:
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加6-12倍量水提取1-3次,每次1-3小时,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量辅料,混合均匀,制粒,干燥,整粒,即得颗粒剂。
以下通过实施例形式的具体实施方式,对本发明的上述内容作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实施例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
具体实施方式
实施例1
金银花5000g、苦参5000g、蛇床子5000g、当归5000g、防风5000g、柿蒂5000g、野菊花3000g、僵蚕3000g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加水提取2次,每次1小时,第一次加10倍量水,第二次加8倍量水,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量碳酸氢钠、硫酸钠、甘草酸二钾、硅石,混合均匀,即得散剂。
实施例2
金银花2200g、苦参2200g、蛇床子2200g、当归2200g、防风2200g、柿蒂2200g、野菊花1400g、僵蚕1400g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加8倍量水提取2次,每次1小时,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量碳酸氢钠、硫酸钠、甘草酸二钾、硅石,混合均匀,即得散剂。
实施例3
金银花6000g、苦参1500g、蛇床子6000g、当归1500g、防风6000g、柿蒂1500g、野菊花5000g、僵蚕1000g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加10倍量水提取2次,每次1小时,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量碳酸氢钠、硫酸钠、甘草酸二钾、硅石,混合均匀,即得散剂。
实施例4
金银花1500g、苦参6000g、蛇床子1500g、当归6000g、防风1500g、柿蒂6000g、野菊花1000g、僵蚕5000g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加12倍量水提取1次,提取3小时,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量碳酸氢钠、硫酸钠、甘草酸二钾、硅石,混合均匀,即得散剂。
实施例5
金银花100g、苦参1000g、蛇床子100g、当归1000g、防风100g、柿蒂1000g、野菊花50g、僵蚕800g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加6倍量水提取3次,每次1小时,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量碳酸氢钠、硫酸钠、甘草酸二钾、硅石,混合均匀,即得散剂。
实施例6
金银花1000g、苦参100g、蛇床子1000g、当归100g、防风1000g、蝉蜕100g、野菊花800g、僵蚕50g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加8倍量水提取2次,每次2小时,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量磷酸三钙、硫代硫酸钠、硫酸钙,混合均匀,即得散剂。
实施例7
金银花220g、苦参220g、蛇床子220g、当归220g、防风220g、柿蒂220g、野菊花140g、僵蚕140g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加水提取2次,每次1小时,第一次加10倍量水,第二次加8倍量水,过滤,合并滤液,滤液减压浓缩至稠膏,干燥,粉碎,得提取物;
取甘油、山梨酸钾适量,加入提取物和适量纯化水溶解,加热,充分搅拌至完全溶解,即为水相;取鲸蜡醇、甘油硬脂酸酯、硬脂醇、辛酸/癸酸三甘油酯、硬脂酸适量,加热至完全溶化,即为油相;搅拌下将水相缓慢加入油相中,停止加热,继续搅拌,冷却至室温,即得软膏剂。
实施例8
金银花500g、苦参500g、蛇床子500g、当归500g、防风500g、柿蒂500g、野菊花300g、僵蚕300g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加10倍量水提取2次,每次1小时,过滤,合并滤液,滤液减压浓缩至稠膏,干燥,粉碎,得提取物;
取甘油、山梨酸钾适量,加入提取物和适量纯化水溶解,加热,充分搅拌至完全溶解,即为水相;取鲸蜡醇、甘油硬脂酸酯、硬脂醇、辛酸/癸酸三甘油酯、硬脂酸适量,加热至完全溶化,即为油相;搅拌下将水相缓慢加入油相中,停止加热,继续搅拌,冷却至室温,即得软膏剂。
实施例9
金银花150g、苦参600g、蛇床子150g、当归600g、防风150g、柿蒂600g、野菊花100g、僵蚕500g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加8倍量水提取2次,每次2小时,过滤,合并滤液,滤液减压浓缩至稠膏,干燥,粉碎,得提取物;
取甘油、山梨酸钾适量,加入提取物和适量纯化水溶解,加热,充分搅拌至完全溶解,即为水相;取鲸蜡醇、甘油硬脂酸酯、硬脂醇、辛酸/癸酸三甘油酯、硬脂酸适量,加热至完全溶化,即为油相;搅拌下将水相缓慢加入油相中,停止加热,继续搅拌,冷却至室温,即得软膏剂。
实施例10
金银花600g、苦参150g、蛇床子600g、当归150g、防风600g、柿蒂150g、野菊花500g、僵蚕100g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加6倍量水提取3次,每次1小时,过滤,合并滤液,滤液减压浓缩至稠膏,干燥,粉碎,得提取物;
取甘油、山梨酸钾适量,加入提取物和适量纯化水溶解,加热,充分搅拌至完全溶解,即为水相;取PEG-75
硬脂酸酯、鲸蜡硬脂醇、硬脂醇、辛酸/癸酸三甘油酯、聚二甲基硅氧烷适量,加热至完全溶化,即为油相;搅拌下将水相缓慢加入油相中,停止加热,继续搅拌,冷却至室温,即得软膏剂。
实施例11
金银花10g、苦参100g、蛇床子10g、当归100g、防风10g、蝉蜕100g、野菊花5g、僵蚕80g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加12倍量水提取1次,提取3小时,过滤,合并滤液,滤液减压浓缩至稠膏,干燥,粉碎,得提取物;
取甘油、山梨酸钾适量,加入提取物和适量纯化水溶解,加热,充分搅拌至完全溶解,即为水相;取鲸蜡醇、鲸蜡醇聚醚-20、卡波姆、环五聚二甲基硅氧烷、硬脂酸适量,加热至完全溶化,即为油相;搅拌下将水相缓慢加入油相中,停止加热,继续搅拌,冷却至室温,即得软膏剂。
实施例12
金银花100g、苦参10g、蛇床子100g、当归10g、防风100g、柿蒂10g、野菊花80g、僵蚕5g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加8倍量水提取2次,每次2小时,过滤,合并滤液,滤液减压浓缩至稠膏,干燥,粉碎,得提取物;
取甘油、山梨酸钾适量,加入提取物和适量纯化水溶解,加热,充分搅拌至完全溶解,即为水相;取PEG-75
硬脂酸酯、甘油硬脂酸酯、硬脂醇、辛酸/癸酸三甘油酯、硬脂酸适量,加热至完全溶化,即为油相;搅拌下将水相缓慢加入油相中,停止加热,继续搅拌,冷却至室温,即得软膏剂。
实施例13
金银花500g、苦参500g、蛇床子500g、当归500g、防风500g、柿蒂500g、野菊花300g、僵蚕300g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加水提取2次,每次1小时,第一次加10倍量水,第二次加8倍量水,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量甘露醇、乳糖、微晶纤维素,混合均匀,制粒,干燥,整粒,即得颗粒剂。
实施例14
金银花300g、苦参300g、蛇床子300g、当归300g、防风300g、柿蒂300g、野菊花200g、僵蚕200g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加10倍量水提取2次,每次1小时,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量的微晶纤维素、甘露醇、糊精,混匀,制粒,干燥,加入适量硬脂酸镁,混匀,压片,包衣或不包衣,即得片剂。
实施例15
金银花400g、苦参400g、蛇床子400g、当归400g、防风400g、柿蒂400g、野菊花150g、僵蚕150g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加8倍量水提取2次,每次2小时,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量辅料,按照常规工艺制成丸剂。
实施例16
金银花250g、苦参450g、蛇床子250g、当归450g、防风250g、柿蒂450g、野菊花180g、僵蚕250g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加8倍量水提取2次,每次1小时,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量乳糖,混匀,制粒,干燥,整粒,装胶囊,即得胶囊剂。
实施例17
金银花250g、苦参250g、蛇床子250g、当归250g、防风250g、柿蒂250g、野菊花150g、僵蚕150g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加10倍量水提取2次,每次1小时,过滤,合并滤液,滤液减压浓缩至稠膏,干燥,粉碎,得提取物;
取增稠剂、保湿剂、透皮剂、防腐剂,加入水、pH调节剂,制成凝胶基质,和提取物混合,搅拌均匀,即得凝胶剂。
实施例18
金银花210g、苦参230g、蛇床子210g、当归230g、防风210g、柿蒂230g、野菊花130g、僵蚕150g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加8倍量水提取2次,每次2小时,过滤,合并滤液,滤液减压浓缩至稠膏,干燥,粉碎,得提取物,加入适量辅料,按常规工艺制成乳膏剂。
实施例19
金银花4000g、苦参2000g、蛇床子4000g、当归2000g、防风4000g、柿蒂2000g、野菊花4000g、僵蚕800g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加10倍量水提取2次,每次1小时,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量氯化钙、硫酸镁、碳酸钾、甘草酸二钾,混合均匀,即得散剂。
实施例20
金银花2500g、苦参3000g、蛇床子2500g、当归3000g、防风2500g、柿蒂3000g、野菊花3000g、僵蚕1200g
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加12倍量水提取2次,每次2小时,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量硅石、甘草酸二钾、磷酸三钙、硫酸钙,混合均匀,即得散剂。
以上均为本发明较佳的实现方案,除此之外,本发明还可以其他实现方式,需要说明的是,在没有脱离本发明发明构思的前提下,任何显而易见的替换均在本发明保护范围之内。
以下通过使用本发明组合物的临床观察来阐述有益效果:
1、治疗方法
治疗组:
治疗一组:实施例1的散剂,加水溶解,外洗患处10-20min,每日1次,1个疗程为10天;
治疗二组:实施例7的软膏剂,涂抹患处,每日2次,1个疗程为10天。
对照组:使用葡萄糖醋氯己定软膏涂抹患处,每日2次,1个疗程为10天。
2、疗效标准
痊愈:湿疹红斑消失,病变皮肤转为正常,暗红色消失。
有效:湿疹红斑明显减少,发作次数减少,瘙痒减轻,病变皮肤未扩散或扩散速度减缓。
无效:症状没有消失或者加重。
反弹:治好后3个月遇到湿热环境仍然发作。
有效率:(痊愈+有效)/患者总数。
反弹率:(痊愈+有效)复发/(痊愈+有效)。
3、试验设计
采用随机、平行对照临床试验设计。将患者随机分为3组,接受10天的相应治疗。患者分别在治疗前和治疗第10天后由同一指标评估者对患者的临床症状与体征进行评估,并详细地记录。治疗结束后第3个月对患者反弹情况进行回访。
4、治疗结果
入选患者共88例,年龄在0-5岁,平均年龄为2岁,将患者随机分为3组,其中治疗一组29人,治疗二组29人,对照组30人,三组患者性别、平均年龄、EASI评分比较差异无统计学意义(P>0.05),因各种原因不能完成本试验的有3例,其中治疗二组1例,对照组2例。详细结果见表1。
表
1
治疗组和对照组治疗以及
3
个月后的反弹情况
组别 | 患者数 | 痊愈 | 有效 | 无效 | 有效率(%) | 反弹 | 反弹率(%) |
治疗一组 | 29 | 27 | 2 | 0 | 100 | 0 | 0 |
治疗二组 | 28 | 27 | 1 | 0 | 100 | 0 | 0 |
对照组 | 28 | 19 | 4 | 5 | 82.1 | 10 | 43.5 |
从表1可以看出,经过10天的治疗,治疗组与对照组有效率比较,具有显著的统计学差异(P<0.01),两个治疗组的有效率均为100%,对照组的有效率为82.1%;两个治疗组与对照组反弹率相比,具有显著的统计学差异(P<0.01),两个治疗组的反弹率均为0,对照组的反弹率为43.5%,且西药治疗具有明显的依赖性,治疗效果明显低于治疗组。
本发明实施例2-6、8-20均按照上述方法进行了相似的试验,结果与上述结果相同。
通过以上数据可见本发明组合物在治疗湿疹有效率高达100%,且见效快,疗效好,不易复发,温和无毒副作用。因此,本发明组合物具有很好的祛湿疹功效。
Claims (13)
1.一种具有祛湿疹功能的组合物,其特征在于,它是由下列重量份的原料药组成:金银花10-100份、苦参10-100份、蛇床子10-100份、当归10-100份、防风10-100份、柿蒂10-100份、野菊花5-80份、僵蚕5-80份。
2.根据权利要求1所述的组合物,其特征在于,它是由下列重量份的原料药组成:金银花15-60份、苦参15-60份、蛇床子15-60份、当归15-60份、防风15-60份、柿蒂15-60份、野菊花10-50份、僵蚕10-50份。
3.权利要求1或2所述组合物的制备方法,其特征在于,它是这样制备的:
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕直接粉碎得到粉末;或加水或不同浓度的乙醇提取,提取液浓缩干燥得粗提物;或进一步采用水提醇沉法、有机溶剂萃取法、柱层析法、二氧化碳超临界萃取法、水蒸气蒸馏法进行精制得到精提物;上述粉末或粗提物或精提物即为所述组合物的有效成分。
4.根据权利要求3所述的制备方法,其特征在于,制得的有效成分加入或不加辅料按常规工艺制成药剂学上可接受的制剂。
5.根据权利要求4所述的制备方法,其特征在于,所述的制剂是指散剂、凝胶剂、软膏剂、乳膏剂、乳剂、搽剂、洗剂、涂膜剂。
6.根据权利要求5所述的制备方法,其特征在于,所述的散剂是这样制备的:
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加6-12倍量水提取1-3次,每次1-3小时,过滤,合并滤液,滤液减压浓缩至稠膏,离心,取上清液,减压浓缩至稠膏,干燥,粉碎,加入适量辅料,混合均匀,即得散剂。
7.根据权利要求6所述的制备方法,其特征在于,所述的辅料是指碳酸氢钠、硫酸钠、硅石、甘草酸二钾、磷酸三钙、硫代硫酸钠、硫酸钙、氯化钙、硫酸镁、碳酸钾。
8.根据权利要求7所述的制备方法,其特征在于,所述的辅料是指碳酸氢钠、硫酸钠、硅石、甘草酸二钾。
9.根据权利要求5所述的制备方法,其特征在于,所述的软膏剂是这样制备的:
将金银花、苦参、蛇床子、当归、防风、柿蒂、野菊花、僵蚕加6-12倍量水提取1-3次,每次1-3小时,过滤,合并滤液,滤液减压浓缩至稠膏,干燥,粉碎,得提取物;
取保湿剂、防腐剂适量,加入提取物和适量纯化水溶解,加热,充分搅拌至完全溶解,即为水相;取乳化剂、稳定剂、润肤剂适量,加热至完全溶化,即为油相;搅拌下将水相缓慢加入油相中,停止加热,继续搅拌,冷却至室温,即得软膏剂。
10.根据权利要求9所述的制备方法,其特征在于,所述的保湿剂是指甘油、丙二醇、丁二醇、异丙醇、透明质酸中的一种或一种以上;防腐剂是指山梨酸钾、山梨酸、羟苯甲酯、羟苯乙酯、羟苯丙酯、苯氧乙醇中的一种或一种以上;乳化剂是指鲸蜡醇、甘油硬脂酸酯、PEG-75 硬脂酸酯、鲸蜡硬脂醇、鲸蜡醇聚醚-20中的一种或一种以上;稳定剂是指硬脂醇、卡波姆中的一种或一种以上;润肤剂是指辛酸/癸酸三甘油酯、硬脂酸、聚二甲基硅氧烷、环五聚二甲基硅氧烷中的一种或一种以上。
11.根据权利要求10所述的制备方法,其特征在于,所述的保湿剂是指甘油;防腐剂是指山梨酸钾;乳化剂是指鲸蜡醇、甘油硬脂酸酯;稳定剂是指硬脂醇;润肤剂是指辛酸/癸酸三甘油酯、硬脂酸。
12.根据权利要求1或2所述的组合物,其特征在于,柿蒂用蝉蜕替代。
13.权利要求1或2或12所述组合物用于制备具有祛湿疹功能的化妆品或药品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610293476.8A CN107343868A (zh) | 2016-05-06 | 2016-05-06 | 一种具有祛湿疹功能的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610293476.8A CN107343868A (zh) | 2016-05-06 | 2016-05-06 | 一种具有祛湿疹功能的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107343868A true CN107343868A (zh) | 2017-11-14 |
Family
ID=60254141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610293476.8A Pending CN107343868A (zh) | 2016-05-06 | 2016-05-06 | 一种具有祛湿疹功能的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107343868A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107898986A (zh) * | 2017-12-01 | 2018-04-13 | 李时珍医药集团有限公司 | 一种温灸膏药及其制备方法 |
CN108126186A (zh) * | 2017-12-28 | 2018-06-08 | 未名生物医药有限公司 | 一种含神经生长因子的水凝胶及其制备方法 |
CN108888556A (zh) * | 2018-07-31 | 2018-11-27 | 北京东方淼森生物科技有限公司 | 一种诺丽活性载体组合物、制备方法及应用 |
CN109549916A (zh) * | 2019-01-16 | 2019-04-02 | 史德良 | 一种改善和治疗湿疹、过敏、口水疹、尿布疹、间擦疹的护肤品组合物及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104013712A (zh) * | 2013-07-17 | 2014-09-03 | 南京海思创新生物科技有限公司 | 治疗小儿皮炎湿疹的中药组合物及其制备方法和应用 |
KR20140121160A (ko) * | 2013-04-05 | 2014-10-15 | 조주현 | 기능성 비누 및 그 제조방법 |
CN104510641A (zh) * | 2013-09-27 | 2015-04-15 | 青岛畅绿生物研究所 | 天然睡莲除湿疹婴儿油 |
CN104873724A (zh) * | 2015-05-28 | 2015-09-02 | 孙启云 | 一种治疗婴幼儿湿疹的中西药外用膏剂 |
CN105079635A (zh) * | 2014-05-12 | 2015-11-25 | 广西农善堂养生保健科技有限公司 | 一种婴儿湿疹润肤药膏 |
CN105288164A (zh) * | 2015-11-30 | 2016-02-03 | 江苏七O七天然制药有限公司 | 一种治疗慢性湿疹的中药组合物及其制备方法 |
-
2016
- 2016-05-06 CN CN201610293476.8A patent/CN107343868A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140121160A (ko) * | 2013-04-05 | 2014-10-15 | 조주현 | 기능성 비누 및 그 제조방법 |
CN104013712A (zh) * | 2013-07-17 | 2014-09-03 | 南京海思创新生物科技有限公司 | 治疗小儿皮炎湿疹的中药组合物及其制备方法和应用 |
CN104510641A (zh) * | 2013-09-27 | 2015-04-15 | 青岛畅绿生物研究所 | 天然睡莲除湿疹婴儿油 |
CN105079635A (zh) * | 2014-05-12 | 2015-11-25 | 广西农善堂养生保健科技有限公司 | 一种婴儿湿疹润肤药膏 |
CN104873724A (zh) * | 2015-05-28 | 2015-09-02 | 孙启云 | 一种治疗婴幼儿湿疹的中西药外用膏剂 |
CN105288164A (zh) * | 2015-11-30 | 2016-02-03 | 江苏七O七天然制药有限公司 | 一种治疗慢性湿疹的中药组合物及其制备方法 |
Non-Patent Citations (3)
Title |
---|
张春凤等主编: "《中药炮制学》", 31 August 2015 * |
袁凤鸣原著: "《新编百草名方大全》", 31 January 2015 * |
高长玉等主编: "《药性歌括四百味评注》", 31 August 2011 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107898986A (zh) * | 2017-12-01 | 2018-04-13 | 李时珍医药集团有限公司 | 一种温灸膏药及其制备方法 |
CN108126186A (zh) * | 2017-12-28 | 2018-06-08 | 未名生物医药有限公司 | 一种含神经生长因子的水凝胶及其制备方法 |
CN108126186B (zh) * | 2017-12-28 | 2021-10-29 | 未名生物医药有限公司 | 一种含神经生长因子的水凝胶及其制备方法 |
CN108888556A (zh) * | 2018-07-31 | 2018-11-27 | 北京东方淼森生物科技有限公司 | 一种诺丽活性载体组合物、制备方法及应用 |
CN108888556B (zh) * | 2018-07-31 | 2021-06-04 | 北京东方淼森生物科技有限公司 | 一种诺丽活性载体组合物、制备方法及应用 |
CN109549916A (zh) * | 2019-01-16 | 2019-04-02 | 史德良 | 一种改善和治疗湿疹、过敏、口水疹、尿布疹、间擦疹的护肤品组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107343868A (zh) | 一种具有祛湿疹功能的组合物及其制备方法 | |
CN102836228B (zh) | 一种治疗结膜炎的中药组合物及其制备方法和应用 | |
CN103182045A (zh) | 一种治疗手足癣的药物及其制备方法 | |
CN101897889A (zh) | 一种治疗小儿肺炎的中药组合物及其制备方法 | |
CN108815435A (zh) | 一种治疗瘙痒性皮肤病的中药组合物及其制剂的制备方法 | |
CN106177746A (zh) | 一种对化学性肝损伤具有辅助保护作用的组合物及其制备方法 | |
CN103751349B (zh) | 一种治疗鼻炎的中药组合物及其制备方法 | |
CN101433598A (zh) | 虎杖预防和治疗胰岛素抵抗及其相关代谢性疾病的用途 | |
CN109197917A (zh) | 防治手足口病的中药复方护理液及其制备方法和应用 | |
CN103768454B (zh) | 一种具有预防和治疗hiv/aids的组合物及其制备方法 | |
CN104435157B (zh) | 一种治疗下尿路感染的中药组合物及其制备方法 | |
CN104510809A (zh) | 地榆或其提取物抗病毒新用途 | |
CN111437300A (zh) | 一种清热燥湿、散风止痒的中药组合物及其制备方法 | |
CN110464755A (zh) | 一种治疗急性肾盂肾炎的中药组合物片剂 | |
CN102552841A (zh) | 一种治疗中风后遗症的中药 | |
CN102940679A (zh) | 治疗痔疮的中药组合物及其制备方法 | |
CN103110737B (zh) | 一种治疗妇科炎症的中药组合物及其制备方法 | |
CN101607009B (zh) | 一种用于治疗感冒的药物组合物 | |
CN103800789A (zh) | 一种健脾补肾的中药组合物及其制备方法 | |
CN101264077B (zh) | 一种木脂素及其在制备抗炎、抗内毒素药物方面的用途 | |
CN109568519A (zh) | 一种用于湿疹的中药组合物及其制备方法 | |
CN103656252B (zh) | 一种治疗女性尿道疾病的中药组合物及其制备方法 | |
CN105617175B (zh) | 一种治疗妇科疾病的中药组合物及其制备方法 | |
CN105535853A (zh) | 一种临床护理上用于治疗褥疮的中药组合物 | |
CN105106561A (zh) | 硝酸咪康唑复方阴道缓释泡腾片及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171114 |